Académique Documents
Professionnel Documents
Culture Documents
Volume 3 | Issue 1
ISSN: 2348-9782
Research Article
Open Access
Department of Pharmaceutical Technology, Ramanbhai Patel College of Pharmacy, Charotar University of Science
and Technology (CHARUSAT), Gujarat, India.
2
Department of Pharmaceutics, Maliba Pharmacy College, Gujarat, India
1
Corresponding author: Patel GC, Department of Pharmaceutical Technology, Ramanbhai Patel College
of Pharmacy, Charotar University of Science and Technology (CHARUSAT), Changa - 388 421, Gujarat,
India, E-mail: gayatripatel.ph@charusat.ac.in
Citation: Patel GC, Prajapati J, Morthana KM, Khunt DM (2015) Formulation and Evalution of Oral
Reconstitutable Suspension of Cefpodoxime Proxetil. J Pharm Drug Devel 3(1): 101. doi: 10.15744/23489782.2.101
Received Date: November 19, 2014 Accepted Date: February 20, 2015 Published Date: February 23, 2015
*
Abstract
Cefpodoxime proxetil (CFPD PRXL) is broad spectrum, third generation cephalosporin; antibiotic. It is extremely bitter taste
resulting in poor patient compliance. The aim of the present work was to prepare drug resin complex (DRC) using ion exchange resin
(Kyron T-114) for taste masking and formulate oral reconstitutable suspension of DRC. DRC was evaluated for effect of variables like
drug:resin ratio, pH, temperature, soaking time of resin, & stirring time. Reconstitutable suspension was prepared using Xanthun gum
and microcrystalline cellulose as suspending agents. Formulated reconstitutable suspension was evaluated for before reconstitution
parameters like flow properties, particle size and drug content and after reconstitution parameters like aesthetic appeal, sedimentation
rate, redispersibility, particle size, viscosity, pH and drug content. Formulated CFPD PRXL reconstitutable suspension has acceptable
sedimentation properties. In evaluating period of 14 days no significant change was observed in pH, viscosity, particle size and drug
content. From the results it is concluded that effective taste masking of Cefpodoxime proxetil was achieve using Kyron T-114 and
successfully evaluated in reconstitutable suspension.
Keywords: Sedimentation Rate; Ion Exchange Resin; Stability
Introduction
Cefpodoxime proxetil, is a third generation cephalosporin antibiotic useful in the treatment of infections of respiratory tract and
urinary tract. Cefpodoxime proxetil is extremely bitter in taste and hampers the oral delivery in paediatrics and geriatrics patients.
Several methods can be employed to mask the bitter taste, like microencapsulation, ion exchange resin, coating etc. [1-3]. Gandhi
R et al. patented on the masking of bitter taste of the cefpodoxime proxetil dry suspension by coating with Eudragit RD 100.
The suspension of cefpodoxime proxetil and combination of binder carrageenan and microcrystalline cellulose was prepared [4].
Fernandez MI et al. patented on the preparation of stable taste masked, pharmaceutical composition comprising a coated, nondisintegrating discrete dosage units, said units comprising of a core comprising one or more cephalosporins such as cefuroxime
axetil and cefpodoxime proxetil and one or more coating layers of lipid [5].
Suspension defined as an intimate mixture of dry, finely divided drug with excipients, which, upon the addition of suitable vehicle,
yields a suspension [6]. Reconstitutable suspension is reconstituted at the time of use and thus can be use as liquid formulation
which avoids swallowing problem. Moreover, stability of products for tropical countries is a great challenge as these products are
exposed to elevated temperatures (up to 40 C) and relative humidity (up to 90%) especially during transport and storage.
Ion exchange resins (IER) are solid insoluble high molecular weight polyelectrolyte that can exchange their mobile ions of equal
charge with the surrounding medium reversibly and stochiometrically. In IER method, weak cation exchange or weak anion
exchange resins are used for taste masking, depending on the nature of drug. Bitter cationic drugs can get adsorbed on to the weak
cation exchange resins of carboxylic acid and form the complex which is absolutely tasteless with no after taste, and at the same
time, its bioavailability is not affected. Further drug resin complex (DRC) can be formulated as lozenges, chewing gum, suspension
or dispersible tablet [7-9].
The objective of present work was to taste mask Cefpodoxime proxetil using ion exchange resin Kyron T-114 and check the
feasibility of incorporating the DRC into reconstitutable suspension to increase patient compliance.
Volume 3 | Issue 1
Preparation DRC
Weight ratio of Kyron T-114 was placed in a beaker containing required quantity of deionized water and allowed to swell for 2 hrs.
Weighed amount of CFPD PRXL was added into it and stirred for 4 hrs. The mixture was filtered and residue was washed with
three portions of 75 ml of deionized water and dried. Bound drug in complex was calculated as drug-loading efficiency. DRC was
optimized for various parameters like drug to resin ratio, effect of pH, effect of temperature, effect of soaking time of resin and
effect of stirring time on taste masking efficiency of drug.
Preparation of oral reconstitutable suspension [10]: The oral reconstitutable suspension of CFPD PRXL was prepared from the
optimized DRC (drug rasin weight ratio 1:3). The formula is presented in Table 1. All the ingredients for suspension were sieved
through mesh no. 40 to make uniform particle size dispersion. The DRC equivalent to 50 mg/ 5 ml of suspension was mixed with
the excipients. The prepared suspension was evaluated for before and after reconstitution parameters.
Ingredients
Functional category
230
Xanthun gum
Suspending agent
30
Microcrystalline cellulose
Suspending agent
50
Sucrallose
Sweetener
10
Mannitol
Filler
50
Methyl paraben
Preservative
10
Propyl paraben
Preservative
Sodium citrate
Buffer
25
Strawberry flavor
Flavoring agent
20
Erythrosine supra
Coloring agent
Evaluation of DRC
Percentage yield: Percentage yield of DRC was calculated using following equation.
% yield =
Practical yield
Theoratical yield
Drug content: DRC equivalent to 100 mg of drug was dissolved in 100 ml 0.1 N Hydrochloric acid in volumetric flask. The mixture
was sonicated for 15 min and filtered using Whatman filter paper. The above solution was suitably diluted to get solution of 10 g/
ml. Drug content was estimated using UV spectrophotometer at 262.5 nm using calibration curve equation. The drug content was
measured using following equation,
Theoretical concentration of CFPD PRXL = 1000g/ml
Practically Obtained CFPD PRXL Concentration
% drug content =
100 [Eq.2]
100
Taste Evaluation [11-13]: The taste of suspension was checked by panel method. The study protocol was explained and written
consent was obtained from volunteers. The optimised DRC and CFPD PRXL were subjected for taste evaluation. Taste evaluation
was performed by testing the samples on 6 volunteers in the age group 2228 years. Each volunteer held DRC equivalent to 25 mg
in the mouth for 30 seconds and then spit out. The scale used was (a) 0-Tasteless, (b) 1-Slightly bitter, (c) 2- Bitter, and (d) 3-Very
bitter.
Volume 3 | Issue 1
Characterization of DRC
Molecular properties on complexation were studied by Fourier transform infrared spectroscopy (FTIR). Infrared spectra of CFPD
PRXL, Kyron T-114 and DRC were obtained using FTIR-8400S, Shimadzu. The pellets were prepared on KBr press, and the spectra
were recorded over the wave number 4000 to 400 cm-1. The spectra were obtained comparatively analyzed.
The formulated suspension was evaluated for physical stability by determining the sedimentation volume. Fifty ml of suspension
was taken in 100 ml stopped graduated measuring cylinder. The suspension was dispersed thoroughly by moving upside down for
three times. Later, the suspension was allowed to settle for three minutes and the volume of sediment was noted. This is the original
volume of sediment (H0). The cylinder was kept undisturbed for 14 days. The volume of sediment read at 0 day, on 7th day and on
the 14th day was considered as final volume of sediment (Hu). The redispersibility of the suspension was checked by moving the
stopered cylinder upside down until there was no sediment at the bottom of the cylinder.
Sedimentation volume= Hu [Eq.3]
H0
Determination of Viscosity
Viscosity study was carried out using a Brookfield viscometer with spindle no. S61. Viscosity was measured at 100 rpm, at 25 C.
pH of the suspension
pH of the suspension was determined using calibrated digital pH meter.
Stability study
The prepared suspension was subjected to short term stability study for a period of three months as per ICH guidelines. In the
present study, stability studies were carried out at 25 C / 60% RH and 40 C / 75% RH up to three months. Photostability chamber
was used. Physical stability was analyzed by change in appearance and chemical stability was analyzed by the change in the drug
content and drug dissolution.
Volume 3 | Issue 1
% drug loading
Bitterness*
1:1
61.54 0.61
1:2
73.03 2.01
1:3
85.78 0.71
1:4
86.64 1.29
1:5
87.29 1.06
* Bitterness level graded from (1) no bitter, (2) less bitter, (3) moderate bitter, (4) bitter
and (5) very bitter
Taste Evaluation
The drug and the DRC of optimized ratio were subjected to taste evaluation. Taste evaluation in volunteers confirmed that the taste
of drug was excellent bitter while in optimized DRC the taste of drug was not appeared.
Flow properties
Table 3 presents the results of micromeritic studies for DRC. The Carrs index value between 5-12% indicates excellent compressibility.
The values of hausners ratio less than 1.25% and angle of repose below 30 indicates good flowability of DRC.
Parameter
Result
0.625 0.018
0.689 0.017
Compressibility index
9.29
Hausners ratio
1.102
Angle of repose ()
28.72 1.45
386 24.3
% yield
85.78 0.71
Assay
99.74 0.88
Figure 1: In-vitro drug release profile of drug-resin complex in 0.1 N HCl, deionized water and simulated salivary pH 6.8
Volume 3 | Issue 1
In 0.1 N HCl more than 80% of drug release was released in 15 min, whereas in simulated salivary pH 6.8 and deionized water, less
than 10% drug was released in 15 min. The exchange process of drug release follows
Resin- - Drug+ + X+ Resin- - X+ + Drug+ [Eq.4]
Where, X+ represents the ions in the GI tract.
The presence of H+ ion in the 0.1 N HCl causes displacement of CFPD PRXL, thus facilitating drug release. The amount of drug
released was insufficient to impart bitter taste in deionized water and simulated salivary pH 6.8 [20].
Characterization of DRC
FTIR Spectroscopy: The FTIR spectra of pure drug showed characteristic peaks at 1724.24 cm1 (C= O stretching) together
with peaks at 1070.42 cm1 and 3492.85 cm1 characterizing C-O stretching of ester group and N-H stretching of amide groups
respectively. The peak at 1328.86 cm1 indicated the presence of aromatic ether in the drug moiety. Significant reduction in the
intensity of distinctive peaks of drug demonstrates the formation of complex between drug and the resin molecule (Figure 2).
Figure 2: Infrared spectra of (a) CFPD PRXL, (b) Kyron T-114 and (c) DRC
Volume 3 | Issue 1
TLC
Rf values of drug and DRC were found to be 0.627 and 0.621 respectively. The Rf value of drug in both reference solution and that
of complex were nearly same indicating that both CFPD PRXL and Kyron T-114 were compatible with each other in prepared DRC
(Figure 3).
Figure 3: TLC plate showing spots of drug (D) and complex (C)
Reconstitution suspension
Prepared suspension was evaluated for flow properties before reconstitution. Results are shown in Table 4. Results showed that
reconstitutable blend has an excellent flow properties and optimum drug content value.
Bulk density (gm/cc)
0.833
0.943
11.66
Hausners ratio
1.13
Angle of repose ()
27.38
426 14.2
97.43 0.547
Hu
Ho
Sedimentation
ratio (Hu/Ho)
Redispersibility
(No. of stroke)
100
100
1.0
80
100
0.80
14
73
100
0.73
Viscosity of suspension
Sedimentation rate depends on the viscosity of the medium. From sedimentation volume data, it can be seen that suspension is
stable and easily redisperse after 14 days. Thus, viscosity of the suspension is sufficient for stability of the suspension.
Volume 3 | Issue 1
pH
The reconstitutable blend for suspension was subjected for stability for a period of 14 days. The samples were reconstituted in
purified water to formulate a suspension. This was analyzed for pH at 0, 7 and 14 days after reconstitution. There was no appreciable
change observed in pH.
Observations
Sr. No
Test
Appearance
Uniform
Uniform
Uniform
Taste
Palatable
Palatable
Palatable
pH
7.0
6.9 0.1
6.9 0.1
0 day
7 days
14 days
Viscosity (cps)
67
60
56
302 8.3
307 6.3
311 10.7
97.22 0.12
96.58 0.54
96.11 0.85
Taste evaluation
Taste evaluation in volunteers confirmed that the taste of bitter drug in reconstitutable suspension was not appeared. All volunteers
found to be tasteless and agreeable of taste of suspension.
Conclusion
In the present study, an attempt was made to mask bitter taste of CFPD PRXL by Kyron T-114 (cation exchange resin). Various
parameters affecting taste masking like drug: resin ratio, pH, temp, soaking time of resin and stirring time were optimized with
efficient loading of drug. The volunteers rated the complexes as tasteless and agreeable. Drug release from DRC in simulated
salivary pH 6.8 and in deionized water was insufficient to impart bitter taste. Complete drug release was observed at gastric pH.
This approach can be utilized for taste masking of bitter pharmaceutical ingredients leading to improved patient compliance.
Taste masked DRC was showed excellent flow properties. Formulated CFPD PRXL reconstitutable suspension has acceptable
sedimentation properties. In evaluating period of 14 days no significant change was observed in pH, Viscosity, particle size and
drug content. This method is simple and cost effective to prepare taste masked reconstitutable suspension of CFPD PRXL that may
be acceptable to the industry.
Annex Publishers | www.annexpublishers.com
Volume 3 | Issue 1
References
1. United States Pharmacopoeial Convention (2009) Published by United States Pharmacopoeial Convention, Rockville, MD, USA, 1853-5.
2. Indian Pharmacopoeia (2010) The Indian pharmacopoeia commission publisher, Ministry of Health and Family Welfare, Ghaziabad, India.
3. Goodman LS, Hardman JG, Limbird LE, Gilman AG, McGraw-Hill (2001) The Pharmacological basis of Therapeutics, Mc Graw Hill Publisher, USA.
4. Gandhi R, Issa C, Malik R (2006) Coating composition for taste masking coating and methods for their application and use. U.S.
5. Fernandez MI, Garriz ES (2008) Trends in pharmaceutical taste masking technologies: A Patent review. U.S.
6. Avari JG, Bhalekar M (2004) Cation exchange resin for taste masking and rapid dissolution of sparfloxacin. Indian drugs 41: 19-23.
7. Sohi H, Sultana Y, Khar RK (2004) Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm 30: 429-48.
8. Pisal S, Zainnuddin R, Nalawade P, Mahadik K, Kadam S (2004) Molecular properties of ciprofloxacin-indion 234 complexes. AAPSPharmSciTech 5: 84-91.
9. Kyron Cross Linked Polymer, Corel Pharma Chem.
10. Rajiv M, Shanker MR, Kamal M, Kumar SS (2004) Taste masked microcapsules and process for their preparation.
11. Lachman L, Liebereman HA, Kanig JL (1986) The Theory and Practice of Industrial Pharmacy (3rd edn) Lea & Febiger publisher, USA.
12. Gennaro AR, Remington (2001) The science and practice of pharmacy Vol I, (20th edn) Lippincott, Williams & Wilkins, A wolter kluwer company, USA.
13. Mauger JW, Robinson DH (1998) Coating technology for taste masking orally administered bitter drugs. U.S.
14. Blas CM, Shah MN. (1993) Taste-masked pharmaceutical suspensions for pharmaceutical actives. European Patent 0556057.
15. Sayed UG, Bajaj AN (2000) Oral controlled release bromhexine ion-exchange resinate suspension formulation. Indian Drugs 37: 185-9.
16. Kuksal K, Pathak K (2008) Use of solubility parameter to design dry suspension of cefaclor as a dual pack system. Ind J Pharm Sci 70: 609-13.
17. Atram SC, Udavant YK, Salunke RJ, Neb GB, Shahi SR, et al. (2009) Formulation of bilayer tablet containing metoprolol succinate and amlodipine besylate as a
model drug for antihypertensive therapy. J Pharm Res 2: 1335-47.
18. Martin A (2004) Physical pharmacy (4th edn) Lippincott Williams and willians, USA.
19. Patvarve VB, Prabhu NB (2005) Taste Masking Of Quinine Sulphate. Ind J Pharm Sci 67: 233-6.
20. Blase CM, Shah MN. (1993) Taste masked pharmaceutical suspensions for pharmaceutical actives. U.S. Patent 5272137.
Volume 3 | Issue 1